欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的 初步判断索拉非尼联合化疗治疗FLT3阳性急性髓系白血病的安全性和有效性,强调FLT3突变等分子细胞遗传学异常对于疗效的重要影响,提高对新的分子靶向治疗的认识.方法 报告1例FLT3-ITD阳性急性单核细胞白血病患者的临床、实验室特征及应用索拉非尼联合化疗对其进行诱导、巩固治疗的经过.结果 患者接受索拉非尼联合化疗诱导及巩固治疗均达到骨髓形态学及分子生物学缓解.治疗过程顺利,药物不良反应轻微、可耐受.结论 索拉非尼可以安全地与化疗联合,对FLT3-ITD阳性患者具有良好疗效.
英文摘要：
Objective To explore the safety and efficacy of sorafenib in combination with chemotherapy for the treatment of FLT3 positive acute myeloid leukemia（ AML）, to highlight the impact of FLT3 mutations and targeting therapy on response of AML. Methods The clinical and laboratory features and the treatment response, especially the safety profile of sorafenib in an acute monocytic leukemia patient with FLT-ITD were reported. Results The patient achieved clinical and molecular CR after sorafenib was added to the second course of combination chemotherapy. The side effects of sorafenib were mild and tolerable. Conclusion The patient responded well to the combination of sorafenib and standard chemotherapy of AML without significant adverse effects.
同期刊论文项目
同项目期刊论文
期刊信息
位置：